BR112023025042A2 - Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas - Google Patents

Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas

Info

Publication number
BR112023025042A2
BR112023025042A2 BR112023025042A BR112023025042A BR112023025042A2 BR 112023025042 A2 BR112023025042 A2 BR 112023025042A2 BR 112023025042 A BR112023025042 A BR 112023025042A BR 112023025042 A BR112023025042 A BR 112023025042A BR 112023025042 A2 BR112023025042 A2 BR 112023025042A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
preparation
compounds
therapeutic application
substituted pyrrol
Prior art date
Application number
BR112023025042A
Other languages
English (en)
Portuguese (pt)
Inventor
Corinne Terrier
Frédéric PETIT
John Macor
Laurent Dubois
Marc Bianciotto
Patrick Bernardelli
Stéphanie Deprets
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21315095.6A external-priority patent/EP4105218A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112023025042A2 publication Critical patent/BR112023025042A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
BR112023025042A 2021-06-15 2022-06-14 Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas BR112023025042A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21315095.6A EP4105218A1 (en) 2021-06-15 2021-06-15 Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP22315117 2022-06-02
PCT/EP2022/066231 WO2022263472A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Publications (1)

Publication Number Publication Date
BR112023025042A2 true BR112023025042A2 (pt) 2024-02-27

Family

ID=82214141

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025042A BR112023025042A2 (pt) 2021-06-15 2022-06-14 Pirrol[2,3-d]pirimidinas substituídas, preparação das mesmas e aplicação terapêutica das mesmas

Country Status (11)

Country Link
US (1) US20240383901A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355748B1 (cg-RX-API-DMAC7.html)
JP (1) JP7886355B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240021910A (cg-RX-API-DMAC7.html)
AU (1) AU2022294022A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025042A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223786A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000083A2 (cg-RX-API-DMAC7.html)
IL (1) IL309195A (cg-RX-API-DMAC7.html)
MX (1) MX2023015016A (cg-RX-API-DMAC7.html)
WO (1) WO2022263472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL330303A (en) * 2023-12-27 2026-08-01 Sanofi Modified pyrrolo[2,3-d]pyrimidins, their preparation and therapeutic applications
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN106146515B (zh) 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
EP3873471B1 (en) 2018-10-31 2025-12-31 Merck Sharp & Dohme LLC N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS: PHARMACEUTICAL COMPOSITIONS AND THEIR USES
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES

Also Published As

Publication number Publication date
JP2024525150A (ja) 2024-07-10
IL309195A (en) 2024-02-01
JP7886355B2 (ja) 2026-07-07
WO2022263472A1 (en) 2022-12-22
KR20240021910A (ko) 2024-02-19
CO2024000083A2 (es) 2024-04-08
US20240383901A1 (en) 2024-11-21
MX2023015016A (es) 2024-05-31
EP4355748A1 (en) 2024-04-24
AU2022294022A1 (en) 2024-02-01
EP4355748C0 (en) 2026-05-13
CA3223786A1 (en) 2022-12-22
EP4355748B1 (en) 2026-05-13

Similar Documents

Publication Publication Date Title
MA59373B1 (fr) [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
BRPI0414111A (pt) inibidores heterocìclicos de mek e métodos de uso dos mesmos
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BR0307819A (pt) Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
BR0308196A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BRPI0807346B8 (pt) derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldeído como inibidores de pkc, seu uso e composição farmacêutica que os compreende
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BR112021011325A2 (pt) Derivados de rapamicina
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2022000598A (es) Preparacion de compuestos antibacterianos.
BR112022009487A2 (pt) Compostos antagonistas do receptor de adenosina
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
BR112022007680A2 (pt) Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
BRPI0511874A (pt) derivados da pirrolopiridina